Drug Profile


Alternative Names: ADXS-DUAL; Second generation axalimogene filolisbac

Latest Information Update: 06 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Advaxis
  • Class Antineoplastics; Cancer vaccines; Gene therapies; Recombinant fusion proteins
  • Mechanism of Action Human papillomavirus E7 protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Cervical cancer

Most Recent Events

  • 06 Jun 2017 Phase-III clinical trials in Cervical cancer (Combination therapy, Metastatic disease) in USA (Parenteral) (Advaxis pipeline, June 2017)
  • 30 May 2017 Advaxis and Bristol-Myers Squibb enter into clincial development collaboration for Cervical Cancer
  • 30 May 2017 Advaxis plans a clinical trial for Cervical cancer (Combination therapy, Metastatic disease, Second line therapy or greater)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top